<DOC>
	<DOC>NCT00406315</DOC>
	<brief_summary>The primary objective of this study is to evaluate change in weight as a result of switching from quetiapine to ziprasidone, in subjects with schizophrenia or schizoaffective disorder who have failed to achieve a satisfactory clinical response to quetiapine due to lack of efficacy or poor tolerability.</brief_summary>
	<brief_title>Study Evaluating The Safety, Tolerability, And Efficacy Of Switching From Quetiapine To Ziprasidone</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Ziprasidone</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<criteria>Males or females, between 18 and 55 years of age, at the time of consent. Subjects must have a primary diagnosis of schizophrenia, any subtype (code 295.xx), or schizoaffective disorder as defined in DSMIVTR (Diagnostic and Statistical Manual of Mental Disorders Fourth Edition) Subjects must have normal vital signs, physical examination, ECG, and laboratory findings except for minor deviations determined and documented to be clinically insignificant by the investigator or a subinvestigator who is a medical doctor. Subjects who are unable to provide informed consent Subjects who meet criteria for a DSMIVTR Axis I (Diagnostic and Statistical Manual of Mental Disorders Fourth Edition) diagnosis other than schizophrenia or schizoaffective disorder, including psychoactive substance abuse or dependence within one year of study entry Females who are pregnant, breast feeding, or lactating at screening.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>ziprasidone, quetiapine (Seroquel) switch, open label, flexible dose, schizophrenia, schizoaffective disorder</keyword>
</DOC>